Abingdon Health PLC
LSE:ABDX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Abingdon Health PLC
Long-Term Debt
Abingdon Health PLC
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Abingdon Health PLC
LSE:ABDX
|
Long-Term Debt
£767k
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
ConvaTec Group PLC
LSE:CTEC
|
Long-Term Debt
$1.5B
|
CAGR 3-Years
5%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
Tristel PLC
LSE:TSTL
|
Long-Term Debt
£4.7m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
Inspecs Group PLC
LSE:SPEC
|
Long-Term Debt
£44.5m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
|
Advanced Medical Solutions Group PLC
LSE:AMS
|
Long-Term Debt
£66.8m
|
CAGR 3-Years
97%
|
CAGR 5-Years
47%
|
CAGR 10-Years
N/A
|
|
|
Rua Life Sciences PLC
LSE:RUA
|
Long-Term Debt
£560k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Abingdon Health PLC
Glance View
Abingdon Health Plc develops, manufactures and commercializes immunoassay tests and reader systems. The company is headquartered in York, North Yorkshire and currently employs 151 full-time employees. The company went IPO on 2020-12-15. The firm operates through three segments: Contract Development, Contract Manufacturing and Product Sales. The Contract Development segment comprises development work for third parties and is recognized over time based on a proportion of completion. The Contract Manufacturing segment comprises contract development and manufacturing activities. The Product Sales segment comprises the sale of ABC-19, pocket diagnostic products, progressive rod cone degeneration (PCRD) tests and antibodies for research use. Its products also include Seralite, which includes Free Light Chain (FLC) Serum. The Company’s geographical market include the United Kingdom, the United States/Canada, rest of world (ROW).
See Also
What is Abingdon Health PLC's Long-Term Debt?
Long-Term Debt
767k
GBP
Based on the financial report for Jun 30, 2025, Abingdon Health PLC's Long-Term Debt amounts to 767k GBP.
What is Abingdon Health PLC's Long-Term Debt growth rate?
Long-Term Debt CAGR 5Y
-9%
Over the last year, the Long-Term Debt growth was -17%. The average annual Long-Term Debt growth rates for Abingdon Health PLC have been -9% over the past three years , -9% over the past five years .
